Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35-74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Scientific reports
Year: 2021, Volume: 11, Pages: 1-12 |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-021-98227-x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41598-021-98227-x Verlag, lizenzpflichtig, Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIArticle&SrcApp=WOS&KeyAID=10.1038%2Fs41598-021-98227-x&DestApp=DOI&SrcAppSID=E1PvrHy7KU93szkb7hP&SrcJTitle=SCIENTIFIC+REPORTS&DestDOIRegistrantName=Springer+Science+and+Business+Media+LLC 
|
| Author Notes: | Volker H. Schmitt, Juergen H. Prochaska, Annegret S. Foell, Andreas Schulz, Karsten Keller, Omar Hahad, Thomas Koeck, Sven-Oliver Troebs, Steffen Rapp, Manfred Beutel, Norbert Pfeiffer, Konstantin Strauch, Karl J. Lackner, Thomas Muenzel, Philipp S. Wild |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780160038 | ||
| 003 | DE-627 | ||
| 005 | 20220820085205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211202s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-021-98227-x |2 doi | |
| 035 | |a (DE-627)1780160038 | ||
| 035 | |a (DE-599)KXP1780160038 | ||
| 035 | |a (OCoLC)1341434609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schmitt, Volker H. |d 1982- |e VerfasserIn |0 (DE-588)1046081969 |0 (DE-627)775696072 |0 (DE-576)399367586 |4 aut | |
| 245 | 1 | 0 | |a Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus |c Volker H. Schmitt, Juergen H. Prochaska, Annegret S. Foell, Andreas Schulz, Karsten Keller, Omar Hahad, Thomas Koeck, Sven-Oliver Troebs, Steffen Rapp, Manfred Beutel, Norbert Pfeiffer, Konstantin Strauch, Karl J. Lackner, Thomas Muenzel, Philipp S. Wild |
| 264 | 1 | |c 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.12.2021 | ||
| 520 | |a Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35-74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (beta - 0.36, 95% CI - 0.63/- 0.09; P = 0.008) and diastolic function (beta 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (beta - 0.34, 95% CI - 0.53/- 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (beta - 0.656, 95% CI - 1.07/- 0.24; P = 0.0021) and diastolic dysfunction (beta 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HRperSD) 1.60, 95% CI 1.39-1.85; P < 0.0001) and all-cause mortality (HRperSD 1.36, 95% CI 1.25-1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function. | ||
| 650 | 4 | |a association | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a heart-failure | |
| 650 | 4 | |a hemoglobin | |
| 650 | 4 | |a impact | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a prognostic value | |
| 650 | 4 | |a risk | |
| 700 | 1 | |a Prochaska, Jürgen |d 1982- |e VerfasserIn |0 (DE-588)1028216246 |0 (DE-627)730455602 |0 (DE-576)375715096 |4 aut | |
| 700 | 1 | |a Föll, Annegret Susanne |e VerfasserIn |0 (DE-588)1216203903 |0 (DE-627)1727461991 |4 aut | |
| 700 | 1 | |a Schulz, Andreas |d 1981- |e VerfasserIn |0 (DE-588)116509665X |0 (DE-627)102928119X |0 (DE-576)510248039 |4 aut | |
| 700 | 1 | |a Keller, Karsten |d 1974- |e VerfasserIn |0 (DE-588)133143589 |0 (DE-627)537504206 |0 (DE-576)299652041 |4 aut | |
| 700 | 1 | |a Hahad, Omar |d 1990- |e VerfasserIn |0 (DE-588)1214326323 |0 (DE-627)1725301989 |4 aut | |
| 700 | 1 | |a Koeck, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Troebs, Sven-Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rapp, Steffen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beutel, Manfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfeiffer, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Strauch, Konstantin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lackner, Karl J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Muenzel, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wild, Philipp S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d [London] : Springer Nature, 2011 |g 11(2021), Artikel-ID 19012, Seite 1-12 |h Online-Ressource |w (DE-627)663366712 |w (DE-600)2615211-3 |w (DE-576)346641179 |x 2045-2322 |7 nnas |a Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g elocationid:19012 |g pages:1-12 |g extent:12 |a Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41598-021-98227-x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIArticle&SrcApp=WOS&KeyAID=10.1038%2Fs41598-021-98227-x&DestApp=DOI&SrcAppSID=E1PvrHy7KU93szkb7hP&SrcJTitle=SCIENTIFIC+REPORTS&DestDOIRegistrantName=Springer+Science+and+Business+Media+LLC |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211202 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 133143589 |a Keller, Karsten |m 133143589:Keller, Karsten |d 910000 |d 910100 |e 910000PK133143589 |e 910100PK133143589 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1780160038 |e 4012643584 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"note":["Gesehen am 02.12.2021"],"title":[{"title_sort":"Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus","title":"Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Schmitt, Volker H.","family":"Schmitt","role":"aut","given":"Volker H."},{"display":"Prochaska, Jürgen","family":"Prochaska","role":"aut","given":"Jürgen"},{"family":"Föll","display":"Föll, Annegret Susanne","given":"Annegret Susanne","role":"aut"},{"given":"Andreas","role":"aut","family":"Schulz","display":"Schulz, Andreas"},{"role":"aut","given":"Karsten","display":"Keller, Karsten","family":"Keller"},{"display":"Hahad, Omar","family":"Hahad","given":"Omar","role":"aut"},{"role":"aut","given":"Thomas","display":"Koeck, Thomas","family":"Koeck"},{"family":"Troebs","display":"Troebs, Sven-Oliver","role":"aut","given":"Sven-Oliver"},{"given":"Steffen","role":"aut","family":"Rapp","display":"Rapp, Steffen"},{"display":"Beutel, Manfred","family":"Beutel","role":"aut","given":"Manfred"},{"family":"Pfeiffer","display":"Pfeiffer, Norbert","given":"Norbert","role":"aut"},{"display":"Strauch, Konstantin","family":"Strauch","role":"aut","given":"Konstantin"},{"display":"Lackner, Karl J.","family":"Lackner","role":"aut","given":"Karl J."},{"role":"aut","given":"Thomas","family":"Muenzel","display":"Muenzel, Thomas"},{"role":"aut","given":"Philipp S.","display":"Wild, Philipp S.","family":"Wild"}],"id":{"doi":["10.1038/s41598-021-98227-x"],"eki":["1780160038"]},"relHost":[{"disp":"Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitusScientific reports","language":["eng"],"note":["Gesehen am 12.07.24"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"[London] ; London","dateIssuedDisp":"2011-","dateIssuedKey":"2011","publisher":"Springer Nature ; Nature Publishing Group"}],"title":[{"title":"Scientific reports","title_sort":"Scientific reports"}],"part":{"pages":"1-12","text":"11(2021), Artikel-ID 19012, Seite 1-12","year":"2021","volume":"11","extent":"12"},"pubHistory":["1, article number 1 (2011)-"],"recId":"663366712","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2615211-3"],"eki":["663366712"],"issn":["2045-2322"]}}],"recId":"1780160038","physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Volker H. Schmitt, Juergen H. Prochaska, Annegret S. Foell, Andreas Schulz, Karsten Keller, Omar Hahad, Thomas Koeck, Sven-Oliver Troebs, Steffen Rapp, Manfred Beutel, Norbert Pfeiffer, Konstantin Strauch, Karl J. Lackner, Thomas Muenzel, Philipp S. Wild"]}} | ||
| SRT | |a SCHMITTVOLGALECTIN3F2021 | ||